ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 134 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,356 | +370.3% | 1,113,582 | +401.1% | 0.07% | +317.6% |
| Q1 2024 | $2,202 | +1137.1% | 222,222 | +562.5% | 0.02% | +750.0% |
| Q3 2023 | $178 | -81.8% | 33,545 | -49.2% | 0.00% | -85.7% |
| Q4 2022 | $977 | -99.9% | 65,995 | +40.3% | 0.01% | +16.7% |
| Q3 2022 | $899,000 | – | 47,055 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |